Evidence map›Paper›PMID 35533313›Full record

ArticleMolecular cancer research : MCR2022

Stromal p53 Regulates Breast Cancer Development, the Immune Landscape, and Survival in an Oncogene-Specific Manner.

Jinghai Wu, Xin Liu, Julie A Wallace Reeser, Anthony J Trimboli, Thierry Pécot, Gina M Sizemore, Shan K Naidu, Soledad A Fernandez, Lianbo Yu, Michael Hallett and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Jinghai WuDepartment of Cancer Biology and Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Xin LiuDepartment of Cancer Biology and Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Julie A Wallace ReeserDepartment of Cancer Biology and Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.ORCID 0000-0003-1113-0014
Anthony J TrimboliDepartment of Cancer Biology and Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Thierry PécotDepartment of Cancer Biology and Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Gina M SizemoreDepartment of Radiation Oncology and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.ORCID 0000-0003-4948-6171
Shan K NaiduDepartment of Cancer Biology and Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Soledad A FernandezDepartment of Biomedical Informatics and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Lianbo YuDepartment of Biomedical Informatics and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Michael HallettDepartment of Biology, Concordia University, Montréal, Quebec, Canada.
Morag ParkDepartment of Biochemistry and Rosalind and Morris Goodman Cancer Centre, McGill University, Montréal, Quebec, Canada.
Gustavo W LeoneDepartment of Cancer Biology and Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Blake E HildrethDepartment of Pathology and O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama.ORCID 0000-0002-4631-1117
Michael C OstrowskiDepartment of Cancer Biology and Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USThe Ohio State University · USMcGill University Health Centre · CACentre National de la Recherche Scientifique · FRMedical College of Wisconsin · USUniversity of Alabama at Birmingham · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
Suppression of Mammary Tumorigenesis by Stromal p53P01CA097189 · NCI · OHIO STATE UNIVERSITY · PI OSTROWSKI, MICHAEL C. · 2004 to 2016
$16.1M
Macrophage and osteoclast specific targeting for the prevention and treatment of breast cancer bone metastasisK01OD026527 · OD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HILDRETH, BLAKE EASON · 2018 to 2022
$634k
NCI NIH HHS P01 CA097189NCI NIH HHS P30 CA016058NIH HHS K01 OD026527
6 · The paper itself

Abstract

Coevolution of tumor cells and adjacent stromal elements is a key feature during tumor progression; however, the precise regulatory mechanisms during this process remain unknown. Here, we show stromal p53 loss enhances oncogenic KrasG12D, but not ErbB2, driven tumorigenesis in murine mammary epithelia. Stroma-specific p53 deletion increases both epithelial and fibroblast proliferation in mammary glands bearing the KrasG12D oncogene in epithelia, while concurrently increasing DNA damage and/or DNA replication stress and decreasing apoptosis in the tumor cells proper. Normal epithelia was not affected by stromal p53 deletion. Tumors with p53-null stroma had a significant decrease in total, cytotoxic, and regulatory T cells; however, there was a significant increase in myeloid-derived suppressor cells, total macrophages, and M2-polarized tumor-associated macrophages, with no impact on angiogenesis or connective tissue deposition. Stroma-specific p53 deletion reprogrammed gene expression in both fibroblasts and adjacent epithelium, with p53 targets and chemokine receptors/chemokine signaling pathways in fibroblasts and DNA replication, DNA damage repair, and apoptosis in epithelia being the most significantly impacted biological processes. A gene cluster in p53-deficient mouse fibroblasts was negatively associated with patient survival when compared with two independent datasets. In summary, stroma-specific p53 loss promotes mammary tumorigenesis in an oncogene-specific manner, influences the tumor immune landscape, and ultimately impacts patient survival. IMPLICATIONS: Expression of the p53 tumor suppressor in breast cancer tumor stroma regulates tumorigenesis in an oncogene-specific manner, influences the tumor immune landscape, and ultimately impacts patient survival.

Indexed as

Breast NeoplasmsOncogenesTumor Suppressor Protein p53AnimalsCarcinogenesisConnective TissueMiceProto-Oncogene Proteins p21(ras)Stromal CellsHras protein, mouseProto-Oncogene Proteins p21(ras)Trp53 protein, mouseTumor Suppressor Protein p53

Identifiers

PMID35533313
PMCPMC9357052
OpenAlexW4229452536

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.